Announcement PDF Appendix 3Y Change of Director’s Interest Notice Appendix 3Y Rule 3.19A.2 Change of Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/09/01 Amended 01/01/11 Name of entity Recce Pharmaceuticals Ltd ABN 73 124 849 065 We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act. Name of Director Dr John Prendergast Date of last notice 27 April 2018 Part 1 - Change of director’s relevant interests in securities In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part. Direct or indirect interest Direct Nature of indirect interest (including registered holder) N/A Date of change 15/02/2019 No. of securities held prior to change Nil Class Fully paid ordinary shares Number acquired 250,000 fully paid ordinary shares Number disposed Nil Value/Consideration Nil cash consideration. The 250,000 fully paid ordinary shares are being issued as part of Dr Prendergast’s remuneration, as approved by shareholders at the Annual General Meeting on 29 November 2018. Note: Provide details of the circumstances giving rise to the relevant interest. Note: If consideration is non-cash, provide details and estimated valuation + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 1 Appendix 3Y Change of Director’s Interest Notice No. of securities held after change 250,000 fully paid ordinary shares Nature of change Issue of 250,000 fully paid ordinary shares, as approved by shareholders at the Annual General Meeting on 29 November 2018. Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buyback Part 2 – Change of director’s interests in contracts Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part. Detail of contract N/A Nature of interest N/A Name of registered holder (if issued securities) N/A Date of change N/A No. and class of securities to which N/A interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed Interest acquired N/A Interest disposed N/A Value/Consideration N/A Interest after change N/A Note: If consideration is non-cash, provide details and an estimated valuation Part 3 – +Closed period Were the interests in the securities or contracts detailed No above traded during a +closed period where prior written clearance was required? If so, was prior written clearance provided to allow the N/A trade to proceed during this period? + See chapter 19 for defined terms. Appendix 3Y Page 2 01/01/2011 Appendix 3Y Change of Director’s Interest Notice If prior written clearance was provided, on what date was N/A this provided? + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 3